PathoVax Named “Best of the Best” of 2015 in Mid-Atlantic Bio Angels 1st Pitch Life Science Competition, Co-Founded by Partner Stephen M. Goodman
Mid-Atlantic Bio Angels (MABA), an angel investor group focused on early-stage life science companies, announced that PathoVax was voted as “Best of the Best” of 2015 at MABA's 1st Pitch Life Science year-end event, which took place at the New York Genome Center in Manhattan on December 7, 2015. The 1st Pitch Life Sciences Best of the Best competition included previous “Best in Show” winners from New York, New Jersey and Philadelphia competitions throughout 2015. Partner Stephen M. Goodman is a co-founder of MABA.
"Commercializing therapeutics is hard, but against six other strong presenters, all of whom were "Best in Show" winners from prior 1st Pitch events, Joshua Wang wowed the audience with his passion regarding the benefits of PathoVax's research and his commitment to moving their technology forward," commented Goodman.
PathoVax describes its technology, RGVax, a broad spectrum HPV vaccine as being expected to provide protection against all clinically relevant HPV types. Pre-clinical peer-reviewed published studies have demonstrated that the RGVax prototype utilizes similar technology as approved vaccines to conserve safety profiles, yet may also provide protection against at least 27 HPVs, including all 15 high-risk cervical cancer-causing types, with one VLP (Virus-Like Particle).
